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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.045Recent evidence has suggested an important role of miRNAs in liver biology and diseases, although the
implication of miRNAs in cholangiocarcinoma remains to be deﬁned further. This study was designed to
examine the biological function and molecular mechanism of miR-101 in cholangiocarcinogenesis and
tumor progression. In situ hybridization and quantitative RT-PCR were performed to determine the
expression of miR-101 in human cholangiocarcinoma tissues and cell lines. Compared with noncancerous
biliary epithelial cells, the expression of miR-101 is decreased in 43.5% of human cholangiocarcinoma
specimens and in all three cholangiocarcinoma cell lines used in this study. Forced overexpression of miR-
101 signiﬁcantly inhibited cholangiocarcinoma growth in severe combined immunodeﬁciency mice. miR-
101-overexpressed xenograft tumor tissues showed decreased capillary densities and decreased levels of
vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2). The VEGF and COX-2 mRNAs
were identiﬁed as the bona ﬁde targets of miR-101 in cholangiocarcinoma cells by both computational
analysis and experimental assays. miR-101 inhibits cholangiocarcinoma angiogenesis by direct targeting
of VEGF mRNA 30untranslated region and by repression of VEGF gene transcription through inhibition of
COX-2. This study established a novel tumor-suppressor role of miR-101 in cholangiocarcinoma and it
suggests the possibility of targeting miR-101 and related signaling pathways for future therapy.
(Am J Pathol 2013, 182: 1629e1639; http://dx.doi.org/10.1016/j.ajpath.2013.01.045)Supported by NIH grants CA102325, CA106280, CA134568, and
DK077776 (T.W.).Cholangiocarcinoma is a highly malignant cancer of the
biliary tree with a dismal prognosis. The incidence and
mortality of cholangiocarcinoma, especially the intrahepatic
type, is increasing worldwide, and currently there is no
effective chemoprevention or treatment. The tumor often
arises from background conditions that cause long-standing
inﬂammation, injury, and reparative biliary epithelial cell
proliferation, such as primary sclerosing cholangitis, clo-
norchiasis, hepatolithiasis, or complicated ﬁbropolycystic
diseases.1e9 The pathogenesis of cholangiocarcinoma is
complex and involves a number of signaling molecules,
including vascular endothelial growth factor (VEGF)10,11
and cyclooxygenase-2 (COX-2).3
VEGF and COX-2 signaling pathways are known to
interact with each other reciprocally and coordinately regulate
cancer growth.12 VEGF is a potent angiogenic factor that
binds to its receptor and stimulates cell proliferation and
survival; human cholangiocarcinoma tissue samples andstigative Pathology.
.cell lines express VEGF.10,11 COX-2 is a rate-limiting key
enzyme for the synthesis of proinﬂammatory and tumorigenic
prostaglandins; consistent with the up-regulation of COX-2 in
cholangiocarcinomas,13e17 the role of COX-2 signaling in
cholangiocarcinoma growth has been well documented.3
Thus, targeting VEGF and COX-2 signaling pathways may
provide effective prevention and treatment of human
cholangiocarcinoma.
miRNAs are small noncoding RNAs that regulate the
expression of target genes post-transcriptionally through base
pairing with target mRNAs.18 In this study, we aimed to
identify miRNAs that are capable of targeting key signaling
pathways in cholangiocarcinogenesis. We performed a
computational analysis using the algorithm provided at
http://www.microrna.org,19,20 and this approach led us to
Zhang et alidentify miR-101 as a noncoding RNA that binds directly to
the 30-untranslated region (UTR) of both VEGF and COX-2
mRNAs. Although miR-101 has been shown to function as
a tumor suppressor in certain cancers by targeting several
molecules including enhancer of zeste homologue 2, COX-2,
amyloid precursor protein, and myeloid cell leukemia
sequence-1,21e25 the potential implication of miR-101 in
cholangiocarcinomas remains unknown. Given that miR-101
is one of the most abundantly expressed miRNAs in the
liver,26 we sought to examine the expression of miR-101 in
human cholangiocarcinoma tissues and to validate the effect
of miR-101 on VEGF and COX-2 in cholangiocarcinoma
cells and their impact on cholangiocarcinogenesis and tumor
progression.
Materials and Methods
Materials
The miR-101-1 expressed lentivirus and scramble control
lentiviral, both co-expressing enhanced green ﬂuorescent
protein, were obtained from GeneCopoeia (Rockville, MD).
Rabbit polyclonal antibody against CD31 and mouse mono-
clonal antibody against Ki-67 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-
body against COX-2 was obtained from Cayman Chemical
(AnnArbor,MI).Mouse monoclonal antibody against b-actin
was obtained from Sigma (St. Louis, MO). IRDye 800CW or
680LT-labeled anti-mouse or rabbit IgG secondary antibody
were purchased fromLI-CORBiosciences (Lincoln, NE). The
VEGF promoter (from 722 to þ 320) luciferase reporter
construct was purchased from Switchgear (Menlo Park, CA)
and the VEGF 30UTR luciferase reporter was purchased from
GeneCopoeia. Prostaglandin E2 (PGE2) was purchased from
CaymanChemical (AnnArbor,MI). Flt-1was purchased from
ProsPec (East Brunswick, NJ). All other analytic grade
chemical reagents were purchased from Sigma.
In Situ Hybridization of miRNA
Human cholangiocarcinoma tissue arrays (ISU ABXIS, Seoul,
Korea) and noncholangiocarcinoma liver specimens were sub-
jected to in situ hybridization (ISH) per institutional review
board approval. ISH was performed using the miR-101 locked
nucleic acid probe (50-digoxigenin-TTCAGTTATCACA-
GTACTGTA-30-digoxigenin) and the microRNA ISH Optimi-
zation Kit (Exiqon, Vedbaek, Denmark) according to the
manufacturer’s instructions. Brieﬂy, deparafﬁnized arrays were
incubated with 15 mg/mL proteinase K at 37C for 8 minutes.
After dehydration, the slides were incubated with 40 nmol/L
miR-101 probe at 50C for 120 minutes, followed by stringent
washes with 5 standard saline citrate, 1 standard saline
citrate, and 0.2 standard saline citrate buffers at 50C, digox-
igenin blocking reagent (Roche, Mannheim, Germany) in
maleic acid buffer containing 2% sheep serum at room tem-
perature for 15 minutes, and alkaline phosphataseeconjugated1630antidigoxigenin (diluted 1:500 in blocking reagent; Roche) at
room temperature for 60 minutes. Enzymatic color was devel-
oped by incubating with 4-nitro-blue tetrazolium and 5-bromo-
4-chloro-30-indolylphosphate substrate (Roche) at 30C for
2 hours to form dark-blue 4-nitro-blue tetrazolium-formazan
precipitate, followed by counterstaining with nuclear fast red
solution (Vector Laboratories, Burlingame, CA). The slides
then were rinsed, dehydrated, mounted, and observed under
a microscope. Scrambled probe and U6 snRNA-speciﬁc probe
were used as a system control. A standard four-point scale was
used to evaluate the staining intensity according to the estab-
lished criteria.27
Cell Culture
Three human cholangiocarcinoma cell lines (CCLP1,
HuCCT1, andTFK1) and one noncancerous cholangiocyte cell
line (H69) were used in this study [the CCLP1 cell line was
established by Theresa Whiteside, Ph.D., at the Pittsburgh
Cancer Institute (Pittsburgh, PA); the HuCCT1 and TFK1 cells
were obtained from the Japanese Cancer Research Resources
Bank (Osaka, Japan); and the H69 cells were kindly provided
by Dr. Gregory J. Gores at the Mayo Clinic College of Medi-
cine (Rochester,MN)]. All cells were cultured according to our
previously describedmethods.28 ThemiR-101eoverexpressed
and scramble control stable cell lines were established by
transduction with miR-101-1 lentiviral vector or miRNA-
scramble control lentiviral vector, followed by selection with
media containing puromycin. For VEGF induction by COX-2
overexpression, the cells transfected with the COX-2 open
reading frame (without 30UTR) plasmid were cultured in Opti-
MEMmedium (Invitrogen, Carlsbad, CA) containing 1% fetal
bovine serum (FBS) for 24 hours and the culture media were
collected for analysis. For VEGF induction by PGE2, the cells
were incubated with Opti-MEM medium (Invitrogen) con-
taining 1% FBS and 10 mmol/L PGE2 for 24 hours.
Anti-miR, miRNA Precursor, and siRNA Transfection
miR-101especiﬁc anti-miR (Qiagen, Valencia, CA), miR-101
precursor (Ambion, Austin, TX), or COX-2 siRNA (Ambion)
and control siRNA were transfected into cells using Oligo-
fectamine (Invitrogen) per the manufacturer’s instructions.
After transfection at the indicated time periods, the cell lysates
or culture supernatants were obtained for analysis.
30UTR Luciferase Reporter Plasmid Construction
The 450-bp 30UTR of human COX-2 was ampliﬁed from
cDNA by PCR with the forward primer 50-AAGCCTTG-
CCTCAGAGAGAACTGTACGGGG-30 and reverse primer
50-CTCGAGTGTGGGCTAGCACATAGGCCT-30 (endo-
nuclease restriction sites were incorporated in primers to
facilitate ligation into the luciferase reporter plasmid pMIR-
REP-dCMV). The correct sequence of the insert was veriﬁed
by DNA sequencing. Generation of the three nucleotideajp.amjpathol.org - The American Journal of Pathology
miR-101 Targets VEGFmutations was achieved by site-directed mutagenesis with
the QuikChange kit from Stratagene (La Jolla, CA), followed
by sequence veriﬁcation. The primers used for the COX-2
30UTR mutation were as follows: 50-CATTGTCACTGA-
CATTTAATGGTGACGTATATTACTTAATTTATTGAA-
G-30 and 50-CTTCAATAAATTAAGTAATATACGTCAC-
CATTAAATGTCAGTGACAATG-30; the primers used for
the VEGF 30UTR mutation were as follows: 50-TTTTTAA-
TTTTAATATTTGTTATCATTTATTTATTGGTGCTCAC-
TTTATCCGTAATAATTGTGGGGAAAAGATATAACA-
TCACG-30 and 50-CGTGATGTTAATATCTTTTCCCCA-
CAATTATTACGGATAAAGGTGAGCACCAATAAAT-
AAATGATAACAAATATTAAAATTAAAAA-30.
Cell Proliferation WST-1 Assay
Cells were cultured in serum-free medium for 24 hours to
synchronize the cell cycle. Cells (2  103) were seeded onto
each well of the 96-well plates in 200 mL culture medium
containing 1% FBS. At the indicated time points, 90 mL of
serum-free medium mixed with 10 mL WST-1 (Roche) was
added to eachwell. After 4 hours of incubation, the absorbance
of each well was measured by an enzyme-linked immuno-
sorbent assay (ELISA) plate reader at a wavelength of 450 nm.
Luciferase Activity Assay
Twenty-four hours after transfection, cells were collected and
analyzed using the Dual-Luciferase Reporter Assay System
(Promega, Fitchburg, WI). Luciferase activity was measured
by a Centro XS3lb 960 microplate ﬂuorescence reader
(Mandel, Ontario, Canada). The pRL-TK plasmid (Promega)
with constitutive expression of Renilla luciferase was co-
transfected with different ﬁreﬂy luciferase-based reporters as
an internal control.
Quantitative RT-PCR
Total RNA was prepared using TRIzol reagent (Invitrogen).
Quantitative RT-PCR (RT-qPCR) was performed using the
Qiagen (Valencia, CA) miScript Kit and the miR-101
Primer Assay. U6 small nuclear 2 was used as an internal
control for miR-101 ampliﬁcation. The primers for COX-2
were as follows: 50-TGAGGGATCTGTGGATGCTTCGT-30
(forward) and 50-AAACCCACAGTGCTTGACACAGAA-30
(reverse); the primers for VEGF were as follows: 50-ACA-
CATTGTTGGAAGAAGCAGCCC-30 (forward) and 50-AG-
GAAGGTCAACCACTCACACACA-30 (reverse); the primers
for the glyceraldehyde-3-phosphate dehydrogenase control
were as follows: 50-GGCCCACATGGCCTCCAAGG-30 (for-
ward) and 50-GGCAGGGACTCCCCAGCAGT-30 (reverse).
Western Blotting
The logarithmically growing cells were washed twice with
ice-cold PBS and lysed in a lysis buffer containing 50mmol/L
HEPES, 1 mmol/L EDTA (pH 8.0); one tablet of proteaseThe American Journal of Pathology - ajp.amjpathol.orginhibitor cocktail (Roche) was added per 10 mL of buffer.
After sonication on ice, the cell lysates were centrifuged at
12,000  g for 20 minutes at 4C and the samples were
subjected to SDS-PAGE. The nitrocellulose membranes
(Bio-Rad, Hercules, CA) were blocked in PBS with 0.1%
Tween 20 containing 5% nonfat milk for 1 hour, followed by
incubation with different primary antibodies (at appropriate
dilutions) in 5% nonfat milk at 4C overnight. After three
washes with PBS with 0.1% Tween 20, the membranes were
incubated with 1:10,000 IRDye 800CW- or IRDye 680-
labeled secondary antibody (LI-CORBiosciences) for 1 hour,
followed by three washes with PBSwith 0.1%Tween 20. The
membranes were scanned with the Odyssey Infrared Imaging
System (LI-COR Biosciences).
PGE2 and VEGF Quantiﬁcation
Cells with indicated treatment were incubated for 24 hours in
1mL serum-free (for PGE2) or 1%FBS containing (for VEGF)
Opti-MEM medium in 6-well plates. The supernatants were
collected and centrifuged for 10 minutes at 12,000  g to
remove the ﬂoating cells and cellular debris. The amounts of
PGE2 and VEGF in the spent media were measured by the
Prostaglandin E2 Biotrak Enzyme Immunoassay System (GE
Healthcare,Piscataway,NJ) and theQuantikineVEGFEnzyme
Immunoassay kit (R&D, Minneapolis, MN), respectively.
Severe Combined Immunodeﬁciency Mouse Zenograft
Studies
Four-week-old male nonobese diabetic CB17-Prkdc/severe
combined immunodeﬁciency (SCID) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). Subcutaneous
xenografts were established by inoculating 1.5  106 miR-
101eoverexpressed or control CCLP1 or HuCCT1 cells in the
ﬂanks of mice (six mice per group). The mice were observed
over 4 weeks for tumor formation. Tumor volume was
measured twice a week with a caliper and calculated by using
the following formula: larger diameter (smaller diameter)2/2.
At sacriﬁce, the tumors were recovered and the wet weight of
each tumorwas recorded. Separate portions of each tumorwere
ﬁxed in formalin forH&E staining and immunohistochemistry,
or snap frozen for Western blotting and RT-qPCR analysis.
Immunohistochemistry and Immunoﬂuorescent
Staining
Deparafﬁnized slidesweremicrowaved for 15minutes in 0.01
mol/L citrate buffer, pH 6.0, to retrieve antigen. For immu-
nohistochemistry (IHC), slides were incubated with 0.3%
H2O2 in methanol for 30 minutes to abolish endogenous
peroxidase activity. The slides were blocked with 10% goat
serum in PBS for 1 hour at 37C and incubated with primary
antibody at 4C overnight, followed by three washes and a
1-hour incubation at room temperature with a secondary
antibody labeled with horseradish peroxidase (for IHC) or1631
Figure 1 Expression of miR-101 in human cholangiocarcinoma tissues
and cell lines. AeD: In situ hybridization for miR-101 in human chol-
angiocarcinoma tissues was performed as described inMaterials and Methods.
Positive signals are shown as dark blue; nuclei are counterstained red. A and C:
Strong staining in the bile duct epithelial cells in the non-neoplastic tissues. B
and D: Weak miR-101 staining in human cholangiocarcinoma cells. Original
magniﬁcation: 400 (A); 100 (B), from the boxed areas. E: RT-qPCR for
mature miR-101 in a human cholangiocyte cell line (H69) and three human
cholangiocarcinoma cell lines (CCLP1,HuCCT1, and TFK1). The results represent
the average ratio between miR-101 and the internal control U6 small nuclear
2 from three experiments. *P < 0.01 compared with H69.
Zhang et alﬂuorescein isothiocyanate (for immunoﬂuorescent staining).
A diaminobenzidine peroxidase substrate kit (Vector Labo-
ratories) was used for IHC color development.
Endothelial Tube Formation Assay (in Vitro
Angiogenesis)
miR-101eoverexpressed or control cells (1  106) were
incubated in 1mLOpti-MEMmedium containing 1%FBS for
24 hours and the supernatantswere collected as the conditioned
media. Primary human umbilical vein endothelial cells (3 
104) in 100 mL 200 Phenol Red Free medium (Invitrogen)
were mixed with 400 mL conditioned medium from the indi-
cated cells and plated on 24-well plates coated with growth
factorereduced Matrigel (Invitrogen). Human umbilical vein
endothelial cells were incubated in a humidiﬁed atmosphere of
5% CO2 at 37C for 3 to 5 hours for tube formation. After
incubation, the cells were stained with Calcein AM (Invi-
trogen) for 30 minutes and examined under a ﬂuorescence
microscope. At least three random images from each experi-
ment (performed in triplicate) were analyzed to calculate the
total tube length and the number of branching points using
ImageJ software version 1.46 (NIH, Bethesda, MD).
Matrigel Plug Assay
Three milliliters of conditioned medium from each cell strain
was condensed to 20 mL by the Centriprep Centrifugal Filter
(Millipore, Billerica, MA) at 4C. The condensed medium then
was mixed with 180 mL reduced growth factor Matrigel (Invi-
trogen) at 0C. The mixtures were injected in the ventral ﬂanks
ofC57BL/6mice subcutaneously using precooled syringes. Ten
days after injection, the gel plugs were recovered from themice.
A portion of each plug was selected for H&E and CD31 IHC
staining. Hemoglobin concentrations in the plugs were
measured using a hemoglobin detection kit from ArborAssays
(Ann Arbor, MI). Per H&E and CD31 IHC staining, a capillary
is deﬁned as a ring or cylindric structure with an internal endo-
thelial cell lining (a lumen) in which red blood cells can be seen.
Statistical Analysis
Data are presented asmeans SEMor SD from aminimum of
three replicates as indicated in each Figure legend. The
differencebetweengroupswas evaluated by statistical software
SPSS13.0 (IMB, Armonk, NY) one-way analysis of variance
or repeated-measures analysis of the generalized linear model.
APvalue less than0.05was considered statistically signiﬁcant.
Results
Expression of miR-101 Is Decreased in Human
Cholangiocarcinoma Tissues and Cell Lines
We performed ISH for miR-101 in 46 cases of human chol-
angiocarcinoma tissues and nine cases of noncholangi-
ocarcinoma liver specimens by using a locked nucleic1632acidemodiﬁed miR-101 probe. Compared with the non-
neoplastic biliary epithelium that lines bile ducts and peri-
biliary glands, the level of miR-101 in cholangiocarcinoma
cells was decreased in 20 cases (20 of 46; 43.5%), unchanged in
26 cases (26 of 46; 56.5%), and increased in 0 cases (0 of
46; 0%). Figure 1, AeD, shows a representative image of miR-
101 ISH, indicating decreased miR-101 in cholangiocarcinoma
tissues in comparison with the non-neoplastic bile ducts. U6
snRNA probe and scrambled probes were hybridizedwith liver
specimens as a systematic control under the same conditions
(Supplemental Figure S1). Consistent with these observations,
RT-qPCR analysis showed lower levels of miR-101 in three
human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and
TFK1) comparedwith the noncancerous human cholangiocyte
cell line, H69 (Figure 1E). These ﬁndings provide novel
evidence for decreased miR-101 expression in human chol-
angiocarcinoma tissues and cell lines.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 miR-101 suppresses human cholangiocarcinoma growth in vivo. A: Construction of human cholangiocarcinoma cell lines with stable over-
expression of miR-101. CCLP1 and HuCCT1 cells were stably transduced with miR-101-1 lentivirus (L/miR101) and control lentivirus (L/control), respectively.
Left panel: Immunoﬂuorescent microscopy for enhanced green ﬂuorescent protein in cells stably transduced with the miR-101-1 lentivirus (this vector carries
the enhanced green ﬂuorescent protein gene under the control of the same cytomegalovirus promoter). Upper row: miR101-1 lentivirus-transduced cells.
lower row: Noninfected control cells. Right panel: RT-qPCR analysis for miR-101 in cells infected with miR-101-1 and scramble control lentivirus. The results
represent means  SEM of the miR-101/U6 small nuclear 2 ratio normalized to the scramble control cells. BeF: miR-101eoverexpressed or scramble control
CCLP1 and HuCCT1 cells (2  106) were inoculated subcutaneously into SCID mice (n Z 6). Thirty days after inoculation, the mice were sacriﬁced and the
tumors were recovered for analyses. B: Xenograft tumor masses from SCID mice (six mice per group; no tumor development in 1 of 6 mice inoculated with miR-
101eoverexpressed HuCCT1 cells). C: The volume of xenograft tumors. The data represent means  SD from six mice. D: The weight of xenograft tumors. The
data represent means  SD from six mice. The bar indicates mean weight of each group. E: The levels of miR-101 in xenograft tumor tissues as determined by
RT-qPCR. The data are shown as the means  SEM from six mice. F: CD31 immunoﬂuorescence staining in xenograft tumor tissues. Left panel: Representative
image of CD31 immunoﬂuorescence (CD31 was shown as green and nuclei were counterstained red). Right panel: Normalized capillary numbers in the tumors
of each group (the data are expressed as means  SD from six mice). Scale bars: 100 mm (A and F). *P < 0.05, **P < 0.01.
miR-101 Targets VEGFmiR-101 Prevents Cholangiocarcinoma Cell Growth
To investigate the role of miR-101 in cholangiocarcinoma
cell growth, we established human cholangiocarcinoma cell
lines (CCLP1 and HuCCT1) with stable overexpression
of miR-101 (the cells were stably transduced with the lenti-
virus particles carrying the miR-101-1 gene or with the
control lentivirus particle carrying the scrambled miRNA).
Successful increase of miR-101 expression in miR-101
lentivirus-transduced cells was veriﬁed by RT-qPCR and byThe American Journal of Pathology - ajp.amjpathol.orgimmunoﬂuorescence for enhanced green ﬂuorescent protein
(Figure 2A). The selected stable cells with or without miR-
101 overexpression then were analyzed for growth in vitro and
in SCID mice. Although miR-101 overexpression slightly
inhibited cholangiocarcinomacell growth in vitro (Supplemental
Figure S2), it signiﬁcantly decreased tumor growth in SCID
mice (Figure 2, BeD). The miR-101eoverexpressed cells
grown in SCID mice formed smaller tumors and had lower
tumor volumes compared with the corresponding controls.
The miR-101eoverexpressed tumors also had decreased1633
Figure 3 VEGF is a direct target of miR-101 in human cholangiocarcinoma cells. A: Putative miR-101 binding sequence in the 30UTR of VEGF mRNA. Three
nucleotides (italics) in the miR-101 binding site were mutated to obtain the mutation reporter construct. B: VEGF 30UTR luciferase reporter activity assay. miR-
101eoverexpressed or control cells were transfected with either wild-type or mutant VEGF 30UTR reporter plasmids (indicated as WT or MU, respectively, on the
x axis). Twenty-four hours after transfection, the cell lysates were obtained to determine luciferase activity by using a luminometer. Renilla luciferase plasmid
was used as the internal control. C: miR-101 reduces VEGF mRNA in cholangiocarcinoma cells. VEGF mRNA levels were determined by RT-qPCR in miR-
101eoverexpressed and miRNA-scramble control cells. The data are shown as means  SEM from three independent experiments. D: miR-101 reduces VEGF
production in cholangiocarcinoma cells. The level of VEGF in cell culture supernatant was determined by enzyme immunoassay. The data are shown as means
SEM from three independent experiments. E: The levels of VEGF mRNA in xenograft tumor tissues as determined by RT-qPCR. The data are shown as means 
SEM from six mice. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; L/control, control lentivirus; L/miR101, miR-101-1 lentivirus. *P< 0.05, **P < 0.01.
Zhang et altumor weight compared with the vector control tumors
(0.52  0.15 versus 0.22  0.070 g, P < 0.01 for CCLP1;
and 0.37  0.16 versus 0.064  0.015 g, P < 0.01 for
HuCCT1). RT-qPCR analysis conﬁrmed an increased miR-
101 level in the tumor tissues with stable transduction of
miR-101 lentivirus (Figure 2E). We noticed that the color of
miR-101eoverexpressed tumors was slightly paler
compared with control tumors, which likely reﬂects less
blood/vasculature in miR-101eoverexpressed tumors. In-
deed, immunoﬂuorescence staining for the vascular endo-
thelial marker CD31 showed decreased blood vessel density
in miR-101eoverexpressed tumors (Figure 2F). The overall
tumor cell proliferation appeared to be slightly reduced in
miR-101eoverexpressed tumors, as indicated by immuno-
staining for the proliferation marker Ki-67; however,
detailed assessment for Ki-67epositive cells was impos-
sible because of the presence of apparent tumor necrosis,
which is known to interfere with immunohistochemical
staining (Supplemental Figure S3A). In areas away from the
necrosis, especially at tumor edges, the tumor cell mor-
phology and the proliferation index did not appear to differ
signiﬁcantly between miR-101eoverexpressed and control
tumors (Supplemental Figure S3, B and C). Thus, the tumor
volume/weight difference between the two groups most
likely is caused by decreased angiogenesis in miR-1011634highly expressed tumors. These ﬁndings suggest that miR-
101 may prevent cholangiocarcinoma growth, at least in
part, through inhibition of angiogenesis.
VEGF Is a Direct Target of miR-101 in Human
Cholangiocarcinoma Cells
Target scan sequence analysis showed the complementary
sequence of miR-101 in the 30UTR of VEGF mRNA
(Figure 3A). To verify the direct effect of miR-101 on
VEGF in cholangiocarcinoma cells, CCLP1 and HuCCT1
cells were transfected with the luciferase reporter plasmid
containing the 30UTR of VEGF mRNA. As shown in
Figure 3B, miR-101 overexpression decreased VEGF
30UTR luciferase reporter activity in CCLP1 and HuCCT1
cells; this effect was abolished when the three nucleotides
in the miR-101 seed-binding site of the VEGF mRNA
30UTR were mutated. Accordingly, real-time PCR and
enzyme immunoassay showed that miR-101 over-
expression decreased VEGF mRNA and protein levels
(Figure 3, C and D). Decreased VEGF mRNA also was
observed in miR-101eoverexpressed xenograft tumor
tissues (Figure 3E). These results show that VEGF is
a direct target of miR-101 in human cholangiocarcinoma
cells.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 miR-101 targets COX-2 in cholangiocarcinoma cells. A: Putative miR-101 binding sequence in the 30UTR of COX-2 mRNA. 30UTR fragments of
COX-2 containing wild-type or mutated (three mutated nucleotides are in italics) miR-101 binding sites were cloned into pMIR-REP-dCMV vector to obtain COX-
2 30UTR luciferase reporter plasmids as described in Materials and Methods. B: COX-2 30UTR luciferase reporter activity assay. miR-101eoverexpressed or control
cells were transfected with either wild-type or mutant COX-2 30UTR reporter plasmids (indicated as WT or MU, respectively, on the x axis). Twenty-four hours
after transfection, the cell lysates were obtained to determine luciferase activity by using a luminometer. Renilla luciferase plasmid was used as the internal
control. C: COX-2 mRNA levels in miR-101eoverexpressed and control cells. COX-2 mRNA was measured by RT-qPCR in miR-101eoverexpressed and miRNA-
scramble control cells. The data are shown as means  SEM from three independent experiments. D: Representative Western blots showing the COX-2
protein levels in miR-101eoverexpressed and control cholangiocarcinoma cells. The numbers under the bands indicate the relative expression levels of
COX-2 proteins (the levels in control cells were set as 1.0). E: PGE2 levels in miR-101eoverexpressed and control cholangiocarcinoma cells. Serum-free medium
of miR-101eoverexpressed and control cells were collected and subjected to enzyme immunoassay analysis for PGE2. The data are presented as means  SEM
of three experiments. F: The levels of COX-2 mRNA in xenograft tumor tissues as determined by RT-qPCR. The data are shown as means  SEM from six mice. G:
Representative Western blots showing decreased COX-2 protein levels in miR-101eoverexpressed tumor tissue recovered from the SCID mice in comparison
with the control tumor tissues. M1 to M6 indicate different mice; the numbers under the bands indicate the relative expression levels of COX-2 proteins (the
levels in control tumors were set as 1.0). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; L/control, control lentivirus; L/miR101, miR-101-1 lentivirus.
*P < 0.05, **P < 0.01.
miR-101 Targets VEGFmiR-101 also Targets COX-2 in Human
Cholangiocarcinoma Cells
Target scan sequence analysis also revealed the presence of
a miR-101 complementary sequence in the 30UTR of COX-2
mRNA (Figure 4A). Thus, we also veriﬁed the direct effect
of miR-101 on COX-2 in cholangiocarcinoma cells by
transfecting CCLP1 and HuCCT1 cells with the luciferaseThe American Journal of Pathology - ajp.amjpathol.orgreporter plasmid containing the 30UTR of COX-2 mRNA. As
shown in Figure 4B, miR-101 overexpression decreased the
COX-2 30UTR luciferase reporter activity and this effect was
abolished when the three nucleotides in the miR-101 seed-
binding site of the COX-2 30UTR were mutated. RT-qPCR
and Western blotting analyses showed that miR-101 over-
expression decreased the levels of COX-2mRNA and protein
(Figure 4, C and D). In contrast, miR-101 inhibition by anti-1635
Figure 5 COX-2/PGE2 activates VEGF transcription in human cholangiocarcinoma cells. AeC: CCLP1 and HuCCT1 cells transfected with the VEGF promoter
luciferase reporter (pVEGF-pro) were co-transfected with COX-2 expression plasmid [COX-2 open reading frame sequence cloned in pcDNA3.0 vector (pCOX2)]
(A), treated with 10 mmol/L PGE2, (B) or co-transfected with the COX-2 siRNA. C: Twenty-four hours later, the cell lysates were obtained to measure luciferase
activities. The data are presented as means  SEM from three independent experiments. D: miR-101eoverexpressed and control cells were transfected with
VEGF promoter luciferase reporter plasmid. Twenty-four hours after transfection, the cell lysates were obtained to measure luciferase activities. The data are
presented as means  SEM from three independent experiments. E: VEGF in supernatants of cells with indicated treatments. The production of VEGF was
increased signiﬁcantly by COX-2 overexpression or 10 mmol/L PGE2 treatment.
yP < 0.01 compared with vehicle or pcDNA3 control. Although miR-
101eoverexpression decreased VEGF production, this effect was prevented by co-treatment with PGE2 or co-expression of COX-2.
zP < 0.01 compared with
corresponding L/control cells and PEG2 treatment or pCOX2 transfected cells. The data are presented as means  SEM from triplicate experiments. F: The cells
were incubated with 1 mg/mL actinomycin D overnight, followed by transfection with miR-101 mimic or scramble control. Left panel: Twenty-four hours later,
VEGF mRNA in cells were determined by RT-qPCR. Right panel: VEGF concentration in culture supernatants was determined by enzyme immunoassay. The data
are shown as means SEM from triplicate experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; L/control, control lentivirus; L/miR101, miR-101-1
lentivirus. *P < 0.05, **P < 0.01.
Zhang et almiR increased the COX-2 protein level in CCLP1 and
HuCCT1 cells (Supplemental Figure S4). Consistent with
these observations, miR-101 overexpression decreased the
production of PGE2 (Figure 4E). Decreased COX-2 mRNA
and protein levels also were observed in miR-101e
overexpressed xenograft tumor tissues recovered from the
SCID mice (Figure 4, F and G).
Contribution of COX-2/PGE2 in miR-101eInduced
Inhibition of VEGF
Given that COX-2/PGE2 signaling is known to stimulate
VEGF gene transcription in other cell types,29e34 we per-
formed further experiments to determine whether down-
regulation of COX-2/PGE2 by miR-101 might contribute
to a reduction of VEGF in cholangiocarcinoma cells. As
shown in Figure 5, AeC, transfection of COX-2 opening
reading frame plasmid or treatment with PGE2 increased
VEGF promoter luciferase reporter activity. On the other
hand, depletion of COX-2 by siRNA reduced VEGF
promoter luciferase reporter activity. These ﬁndings show
a direct role of COX-2/PGE2 signaling in VEGF transcrip-
tion in cholangiocarcinoma cells. Consistent with a reduc-
tion of COX-2/PGE2 by miR-101, miR-101 overexpression1636decreased VEGF promoter luciferase reporter activity in
CCLP1 and HuCCT1 cells (Figure 5D). Furthermore, the
production of VEGF was increased in CCLP1 and HuCCT1
cells with COX-2 overexpression or PGE2 treatment
(Figure 5E). These results provide evidence for inhibition of
COX-2/PGE2 by miR-101, leading to repression of VEGF
gene transcription in cholangiocarcinoma cells.
We noticed that the levels of VEGF in miR-101e
overexpressed and control cells continued to differ when both
cells were transfected with the COX-2 open reading frame
plasmid or were treated with PGE2 (Figure 5E). This ﬁnding
suggests that COX-2/PGE2 signaling only partially contributes
to miR-101emediated inhibition of VEGF in cholangi-
ocarcinoma cells. Consistent with this assertion, we noticed
that when CCLP1 and HuCCT1 cells were pretreated with the
transcription inhibitor actinomycin D (to eliminate COX-2/
PGE2emediated VEGF gene transcription), miR-101 con-
tinued to decrease VEGF mRNA and protein (Figure 5F).
Although overexpression of miR-101 facilitated VEGF
mRNA degradation at 4, 8, and 12 hours, inhibition of miR-
101 by anti-miR prevented VEGF mRNA degradation at
these time points (Supplemental Figure S5). Thus, miR-101
decreases VEGF production in human cholangiocarcinoma
cells through targeting the VEGF mRNA 30UTR as well asajp.amjpathol.org - The American Journal of Pathology
Figure 6 miR-101 suppresses tube formation of
human umbilical vein endothelial cells in vitro.
Human umbilical vein endothelial cells (3 104) in
100 mL 200PRF medium were mixed with 400 mL
conditional medium from indicated cells and plated
in 24-well plates coated with growth factore
reduced Matrigel. The cells were incubated for 3 to
5 hours and stained with Calcein AM before immu-
noﬂuorescence microscopy. A: Representative
images of human umbilical vein endothelial cell
tube formation. B: Upper panel: Normalized tube
length of cells with indicated transduction or
treatment. Lower panel: Branching points of cells
with indicated transduction or treatment. The tube
length and branching point of each scramble
control was set as 100%. The data are expressed as
means SEM from three independent experiments.
L/control, control lentivirus; L/miR101, miR-101-1
lentivirus. *P < 0.05, **P < 0.01.
miR-101 Targets VEGFthrough inhibiting VEGF gene transcription via COX-2/
PGE2.miR-101 Inhibits Cholangiocarcinoma Angiogenesis
in Vitro and in Vivo
Given that miR-101 inhibits VEGF production in chol-
angiocarcinoma cells, we next assessed the angiogenesis
capability of the conditioned media derived from miR-
101eoverexpressed cholangiocarcinoma cells by using
complementary in vitro and in vivo assays. For the in vitro
assay, human umbilical vein endothelial cells were incu-
bated with the conditioned media collected from human
cholangiocarcinoma cells transduced with the miR-101 or
control lentivirus. As shown in Figure 6, the relative
capillary tube length and numbers of branch points were
signiﬁcantly lower in human umbilical vein endothelial cells
incubated with the miR-101 conditioned medium; this
phenomenon no longer was observed in the presence of
soluble VEGF receptor 1, Flt-1. For the in vivo assay,
concentrated conditioned media of miR-101eoverexpressed
CCLP1 and HuCCT1 cells and their respective scrambled
control cells were mixed with Matrigel and injected
subcutaneously into the ventral ﬂank of C57BL/6 mice (10
days after the injection the Matrigel plugs were recovered
for further analysis). As shown in Figure 7A, the miR-101
plugs were a paler color and had lower hemoglobin
concentrations compared with the control plugs. Histologic
examination (H&E stain) and immunostaining for the
vascular endothelial marker CD31 showed decreased
capillary numbers in the miR-101 plugs compared with theThe American Journal of Pathology - ajp.amjpathol.orgcontrol plugs (Figure 7, B and D). These results, together
with the blood vessel analysis of xenograft tumor tissues
from SCID mice (Figure 2F), show that miR-101 inhibits
cholangiocarcinoma angiogenesis.
Discussion
This study showed novel evidence for the expression,
function, and mechanism of miR-101 in human chol-
angiocarcinoma. We showed that the level of miR-101 is
decreased in approximately 43% of human cholangiocar-
cinomas and that miR-101 inhibits cholangiocarcinoge-
nesis and tumor progression. The anticholangiocarcinoma
effect of miR-101 is mediated predominantly through the
inhibition of angiogenesis rather than through inhibition
of tumor cell proliferation. This assertion is supported by
the following observations1: the conditioned medium from
miR-101eoverexpressed cholangiocarcinoma cells
decreased angiogenesis in vitro and in vivo,2 miR-101
overexpression only slightly decreased cholangiocar-
cinoma cell proliferation, and3 miR-101eoverexpressed
cholangiocarcinoma in SCID mice showed decreased
blood vessel density.
Our ﬁndings showed that miR-101 inhibits cholangi-
ocarcinoma angiogenesis by targeting the 30UTR of VEGF
mRNA and by repressing VEGF gene transcription (via
inhibition of COX-2/PGE2) (Figure 7C). Direct targeting of
VEGF by miR-101 is indicated by the following observa-
tions1: a complementary sequence of miR-101 is present in
the 30UTR of VEGF mRNA,2 miR-101 overexpression
decreases VEGF 30UTR luciferase reporter activity in1637
Figure 7 miR-101 suppresses angiogenesis
in vivo. The Matrigel plug assay was performed by
s.c. injection of a 200-mL Matrigel plug into
C56B/6 mice. Plugs were removed after 10 days
and portions of each plug were homogenized for
a hemoglobin assay or ﬁxed for H&E or immuno-
histochemical staining. A: Upper panels: Matrigel
plugs recovered from mice (n Z 3). Lower panel:
Normalized hemoglobin levels in the plugs. Data
are shown as means  SEM from three plugs. B:
The average number of capillaries in plugs from
each group. A qualiﬁed capillary was deﬁned as
a ring or cylindric structure with an internal
endothelial cell lining (CD31þ) with red blood cells
in it. Data represent means  SD from three plugs.
C: Schematic representation of the mechanisms by
which miR-101 regulates cholangiocarcinoma
angiogenesis. D: Repetitive images of H&E stain
and CD31 immunostain. Insets are the enlarged
images of areas highlighted by the green rectan-
gles; arrows indicate capillaries. L/control,
control lentivirus; L/miR101, miR-101-1 lentivirus.
*P < 0.05.
Zhang et alcholangiocarcinoma cells and this effect was abolished by
mutation of the miR-101 binding site, and3 miR-101 over-
expression decreases VEGF mRNA and protein levels in
cholangiocarcinoma cells and this phenomenon persists with
inhibition of transcription by actinomycin D. To our
knowledge, this is the ﬁrst study to show that miR-101 targets
VEGF in human cells.
In parallel, our data further indicate that miR-101 also
binds to the complementary sequence in the 30UTR of
COX-2 mRNA, leading to a decrease of COX-2 protein
translation and a subsequent reduction of PGE2 synthesis.
The latter observation is consistent with a recent study by
Strillacci et al22 that showed that miR-101 targets COX-2 in
human colon cancer cells. Interestingly, Strillacci et al35
also showed that COX-2/PGE2 can regulate miR-101
expression negatively in colorectal cancer cells. Thus, the
interplay between miR-101 and COX-2 signaling pathways
likely is important for the regulation of carcinogenesis and
tumor progression. Given the documented inhibition of
COX-2 by miR-101, it is conceivable that loss of miR-101
may contribute to the up-regulation and ampliﬁcation of
COX-2/PGE2 signaling during the multiple steps of the
carcinogenic process. On the other hand, it also is possible
that activation of COX-2/PGE2 signaling during carcino-
genesis may represent a key mechanism for the reduction of
miR-101 in cancer tissues. In this study, we showed that1638COX-2/PGE2 and miR-101 inﬂuenced VEGF level in
cholangiocarcinoma cells through both transcriptional and
post-transcriptional regulation. The role of COX-2/PGE2
signaling in VEGF gene transcription in cholangiocar-
cinoma cells is corroborated further by the observations that
COX-2 transfection or PGE2 treatment increases VEGF
promoter activity and protein synthesis whereas siRNA
depletion of COX-2 reduces VEGF promoter reporter
activity. Thus,miR-101 decreasesVEGF transcription in cho-
langiocarcinoma cells, at least in part, through inhibition of
COX-2/PGE2.
Su et al23 showed that miR-101 inhibits hepatocellular
carcinoma growth and the effect is mediated in part through
targeting Mcl-1. In our study, we observed that miR-101 did
not signiﬁcantly inﬂuence the level of Mcl-1 protein in human
cholangiocarcinoma cells. Thus, miR-101 may inhibit hepatic
cancer growth by targeting different molecules based on
speciﬁc tumor types and their signaling networks.
In summary, this study provided novel evidence that
miR-101 inhibits cholangiocarcinoma angiogenesis by tar-
geting VEGF directly and indirectly via inhibition of COX-
2ederived PGE2 signaling. Our ﬁndings, along with the
work of Su et al,23 warrant further investigation to explore
the possibility of miR-101 therapy for hepatocellular carci-
noma and cholangiocarcinoma, the two most common
primary cancers of the liver.ajp.amjpathol.org - The American Journal of Pathology
miR-101 Targets VEGFSupplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.01.045.
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